These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 16303861)

  • 1. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
    Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
    Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
    Raoul JL; Van Laethem JL; Peeters M; Brezault C; Husseini F; Cals L; Nippgen J; Loos AH; Rougier P
    BMC Cancer; 2009 Apr; 9():112. PubMed ID: 19366444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
    Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G
    BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
    Arnold D; Höhler T; Dittrich C; Lordick F; Seufferlein T; Riemann J; Wöll E; Herrmann T; Zubel A; Schmoll HJ
    Ann Oncol; 2008 Aug; 19(8):1442-1449. PubMed ID: 18441330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
    Hofheinz R; Hartung G; Samel S; Emig M; Pilz L; Willeke F; Hochhaus A; Hehlmann R; Queisser W
    Anticancer Drugs; 2002 Nov; 13(10):999-1004. PubMed ID: 12439333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
    Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Lee SS; Kim MK; Sym SJ; Lee JS; Kang YK
    J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S98-S103. PubMed ID: 17923763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
    Garufi C; Torsello A; Tumolo S; Ettorre GM; Zeuli M; Campanella C; Vennarecci G; Mottolese M; Sperduti I; Cognetti F
    Br J Cancer; 2010 Nov; 103(10):1542-7. PubMed ID: 20959822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
    Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
    Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
    Tabernero J; Ciardiello F; Rivera F; Rodriguez-Braun E; Ramos FJ; Martinelli E; Vega-Villegas ME; Roselló S; Liebscher S; Kisker O; Macarulla T; Baselga J; Cervantes A
    Ann Oncol; 2010 Jul; 21(7):1537-1545. PubMed ID: 19940007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Hofheinz RD; Gnad-Vogt U; Wein A; Saussele S; Kreil S; Pilz L; Hehlmann R; Hochhaus A
    Anticancer Drugs; 2005 Jan; 16(1):39-45. PubMed ID: 15613902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
    Bouzid K; Khalfallah S; Tujakowski J; Piko B; Purkalne G; Plate S; Padrik P; Serafy M; Pshevloutsky EM; Boussard B;
    Ann Oncol; 2003 Jul; 14(7):1106-14. PubMed ID: 12853354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
    Moehler M; Mueller A; Trarbach T; Lordick F; Seufferlein T; Kubicka S; Geißler M; Schwarz S; Galle PR; Kanzler S;
    Ann Oncol; 2011 Jun; 22(6):1358-1366. PubMed ID: 21119032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.